Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: The BIG 1-98 trial

Journal of Clinical Oncology

Volumn 26, Issue 12, 2008, Pages 1972-1979

  Crivellari, Diana ^a   Sun, Zhuoxin ^a   Coates, Alan S ^a   Price, Karen N ^a   Thürlimann, Beat ^a   Mouridsen, Henning ^a   Mauriac, Louis ^a   Forbes, John F ^a   Paridaens, Robert J ^a   Castiglione Gertsch, Monica ^a   Gelber, Richard D ^a   Colleoni, Marco ^a   Láng, István ^a   Del Mastro, Lucia ^a   Gladieff, Laurence ^a   Rabaglio, Manuela ^a   Smith, Ian E ^a   Chirgwin, Jacquie H ^a   Goldhirsch, Aron ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

LETROZOLE; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; NITRILE; TRIAZOLE DERIVATIVE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; FRACTURE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PATIENT COMPLIANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; THROMBOEMBOLISM; TREATMENT OUTCOME; AGE; BREAST TUMOR; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; MIDDLE AGED; MULTICENTER STUDY; POSTMENOPAUSE;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CARDIOVASCULAR DISEASES; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, BONE; HUMANS; MIDDLE AGED; NITRILES; PATIENT COMPLIANCE; POSTMENOPAUSE; TAMOXIFEN; TRIAZOLES;

EID: 42949164467     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.14.0459     Document Type: Article

References (38)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
2. Winer EP, Hudis C, Burstein HJ et al: American Society of Clinical Oncology Technology Assessment on the use of Aromatase Inhibitors as adjuvant therapy for postmenopausal women with hormone-receptor-positive breast cancer: Status Report 2004. J Clin Oncol 23:619-629, 2005
3. McDonald CC, Alexander FE, Whyte BW, et al: Cardiac and vascular morbidity in women receiving adjuvant tamoxifen for breast cancer in a randomized trial: The Scottish Cancer Trials Breast Group. BMJ 311:977-980, 1995
4. Geisler J, Haynes B, Anker G, Dowsett M, Lonning PE: Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. J Clin Oncol 20:751-757, 2002
5. Lønning PE: Aromatase inhibitors in breast cancer. Endocr Relat Cancer 11:179-189, 2004
6. Hamilton A, Piccart M: The third generation non-steroidal aromatase inhibitors: A review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Ann Oncol 10:377-384, 1999
7. Ellis MJ, Coop A, Singh B, et al: Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1 and/or ErbB-2-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 19:3808-3816, 2001
8. Paridaens R, Dirix L, Lohrisch C, et al: Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14:1391-1398, 2003
9. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003
10. BIG 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353:2747-2757, 2005
11. Coates AS, Keshaviah A, Thürlimann B, et al: Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 25:486-492, 2007
12. Bonetti M, Gelber RD: A graphical method to assess treatment covariate interactions using the Cox model on subsets of the data. Stat Med 19:2595-2609, 2000
13. Bonetti M, and Gelber, R: Covariates and the pattern of treatment effects in clinical trials. Biostatistics 5:465-481, 2004
14. Agresti A: Exact inference for categorical data: Recent advances and continuing controversies. Stat Med 20:2709-2722, 2001
15. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
16. Gray RJ: A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 16:1141-1154, 1988
17. American Heart Association: Heart Disease and Stroke Statistics - 2005 Update. Dallas, TX, American Heart Association, 2005
18. Yancik R, Wesley MN, Ries LA, et al: Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA 285:885-892, 2001
19. Bonow RO, Smaha LA, Smith SC Jr, et al: World Heart Day 2002: The international burden of cardiovascular disease: Responding to the emerging global epidemic. Circulation 106:1602-1605, 2002
20. Hamilton PJ, Allardice PJM, Ogston D, et al: The effect of age upon the coagulation system. J Clin Pathol 27:980-982, 1974
21. Greenland P, Knoll MD, Stanlep J, et al: Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 209:891-897, 2003
22. Thom T, Haase N, Rosamond W, et al: Heart disease and stroke statistics - 2006 update. Circulation 14:1-67, 2006
23. Morales M, Santana N, Soria A, et al: Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer. Breast Cancer Res Treat 40:265-270, 1996
24. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity and postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen: The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 85:1398-1406, 1993
25. Liu CL, Yang TL: Sequential changes in serum triglyceride levels during adjuvant tamoxifen therapy in breast cancer patients and the effect of dose reduction. Breast Cancer Res Treat 79:11-16, 2003
26. Reis SE, Costantino JP, Wickerham L, et al: Cardiovascular effects of tamoxifen in women with and without heart disease: Breast Cancer Prevention Trial. J Natl Cancer Inst 93:16-21, 2001
27. Barrett-Connor E, Mosca L, Collins P, et al: Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137, 2006
28. Braithwaite RS, Chlebowski RT, Lau J, et al: Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med 18: 937-947, 2003
29. Perez EA, Josse RG, Pritchard KI, et al: Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA. 17. J Clin Oncol 24:3629-3635, 2006
30. Howell A: On behalf of the ATAC Trialists' Group Effect of anastrozole on bone mineral density: 2-year results of the Arimidex (anastrozole), Tamoxifen, Alone or in Combination (ATAC) trial. Breast Cancer Res Treat 82:S27, 2003 (suppl 1)
31. Coleman RE, Banks LM, Hall E, et al: Intergroup exemestane study: 1 year results of the bone subprotocol. Breast Cancer Res Treat 88:535, 2004 (suppl 1)
32. Weinstein L, Ullery B, Bourguignon C: A simple system to determine who needs osteoporosis screening. Obstet Gynecol 93:757-760, 1999
33. Hillner BE, Ingle JN, Chlebowski RT, et al: American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 21:4042-4057, 2003
34. Ravdin PM: Managing the risk of osteoporosis in women with a history of early breast cancer. Oncology (Huntingt) 18:1385-1390, 1393, 1394, 2004
35. Braithwaite RS, Col NF, Wong JB: Estimating fracture morbidity, mortality and costs. J Am Geriatr Soc 51:364-370, 2003
36. Allolio B: Risk factors for hip fracture not related to bone mass and their therapeutic implications. Osteoporosis Int 9:S9-S16, 1999 (suppl)
37. Crivellari D, Price K, Gelber RD, et al: Adjuvant endocrine therapy compared with no systemic therapy for elderly women with early breast cancer: 21-year results of International Breast Cancer Study Group Trial IV. J Clin Oncol 21:4517-4523, 2003
38. Long BJ, Jelovac D, Handratta V, et al: Therapeutic strategies using the aromatase inhibitor letrozole and tamoxifen in a breast cancer model. J Natl Cancer Inst 96:456-465, 2004